3. Global SYMPLICITY Registry Locations and Inclusion Criteriaa,b

4. SYMPLICITY Registry Major Adverse Events

5. SYMPLICITY Registry Change in Office SBP

6. SYMPLICITY Registry High Baseline BP Subset

7. SYMPLICITY Registry Design Implications for Clinical Practicea,b

8. Treatment Effectiveness in RDN Response Assessment

9. SYMPLICITY Registry Predictors of RDN Response

10. Number and Types of Comorbidities RDN Response

11. Biomarkers of RDN Effectiveness Current and Future Directions

12. SYMPLICITY HTN-3 Resultsa,b

13. SYMPLICITY HTN-3 Subgroup Analyses

14. SYMPLICITY HTN-3 Medication Changesa

15. SYMPLICITY HTN-3 Medication Types

16. SYMPLICITY HTN-3 Medication Types (cont)a

17. SYMPLICITY HTN-3 African-American Population

18. SYMPLICITY HTN-3 African-American Population (cont)a

19. SYMPLICITY HTN-3 African-American Population (cont)a

20. SYMPLICITY HTN-3 Procedural Effects – No. of Ablations

21. SYMPLICITY HTN-3 Procedural Effects – Circumferentiality

22. Other RDN Procedural Factors

23. Conclusions RDN Moving Forward

24. Abbreviations

25. References

26. References (cont)

27. References (cont)

28. References (cont)